387 related articles for article (PubMed ID: 12928467)
1. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
Roberts R; Rodriguez W; Murphy D; Crescenzi T
JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
[TBL] [Abstract][Full Text] [Related]
2. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
3. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
4. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
[TBL] [Abstract][Full Text] [Related]
5. Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
Benjamin DK; Smith PB; Murphy MD; Roberts R; Mathis L; Avant D; Califf RM; Li JS
JAMA; 2006 Sep; 296(10):1266-73. PubMed ID: 16968851
[TBL] [Abstract][Full Text] [Related]
6. Stimulation programs for pediatric drug research--do children really benefit?
Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J
Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
[TBL] [Abstract][Full Text] [Related]
7. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
8. Pediatric research: coming of age in the new millennium.
Milne CP
Am J Ther; 1999 Sep; 6(5):263-82. PubMed ID: 11329108
[TBL] [Abstract][Full Text] [Related]
9. The impact of the written request process on drug development in childhood cancer.
Snyder KM; Reaman G; Avant D; Pazdur R
Pediatr Blood Cancer; 2013 Apr; 60(4):531-7. PubMed ID: 23335552
[TBL] [Abstract][Full Text] [Related]
10. Current regulatory policies regarding pediatric indications and exclusivity.
Rodriguez WJ; Roberts R; Murphy D
J Pediatr Gastroenterol Nutr; 2003; 37 Suppl 1():S40-5. PubMed ID: 14685077
[TBL] [Abstract][Full Text] [Related]
11. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
12. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
13. Drug labeling and exposure in neonates.
Laughon MM; Avant D; Tripathi N; Hornik CP; Cohen-Wolkowiez M; Clark RH; Smith PB; Rodriguez W
JAMA Pediatr; 2014 Feb; 168(2):130-6. PubMed ID: 24322269
[TBL] [Abstract][Full Text] [Related]
14. Extrapolation of adult data and other data in pediatric drug-development programs.
Dunne J; Rodriguez WJ; Murphy MD; Beasley BN; Burckart GJ; Filie JD; Lewis LL; Sachs HC; Sheridan PH; Starke P; Yao LP
Pediatrics; 2011 Nov; 128(5):e1242-9. PubMed ID: 22025597
[TBL] [Abstract][Full Text] [Related]
15. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
Mathis LL; Iyasu S
Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
[TBL] [Abstract][Full Text] [Related]
16. [What's new in pediatric pharmacology?].
Tréluyer JM; Pons G
Arch Pediatr; 2000 Dec; 7(12):1330-8. PubMed ID: 11147070
[TBL] [Abstract][Full Text] [Related]
17. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
Field MJ; Ellinger LK; Boat TF
Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
[TBL] [Abstract][Full Text] [Related]
18. Ensuring safe and effective medications for children.
Budetti PP
JAMA; 2003 Aug; 290(7):950-1. PubMed ID: 12928474
[No Abstract] [Full Text] [Related]
19. Safety monitoring of drugs receiving pediatric marketing exclusivity.
Smith PB; Benjamin DK; Murphy MD; Johann-Liang R; Iyasu S; Gould B; Califf RM; Li JS; Rodriguez W
Pediatrics; 2008 Sep; 122(3):e628-33. PubMed ID: 18762496
[TBL] [Abstract][Full Text] [Related]
20. [Survey on common pediatric drugs for renal diseases].
Ye WQ; Liang Y; Cui YM; Ding J
Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):888-91. PubMed ID: 24495757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
